The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression (P-TRD)
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression (P-TRD)
Brief Summary:
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression
Detailed Description:
The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression - a dose-ranging studyµ
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 216 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
Actual Study Start Date: January 1, 2019
Estimated Primary Completion Date: May 2021
Estimated Study Completion Date: December 2021
Arms:
- Experimental: Low dose
- Experimental: Medium dose
- Experimental: High dose
| Category | Value |
|---|---|
| Study type(s) | Interventional |
| Expected enrolment | 216 |
| Study start date | 01 January 2019 |
| Estimated primary completion date | 01 May 2021 |